Aarti Pharmalabs reported Q3 FY26 operational revenue of 425.3 Cr, a 9.7% decline year-over-year.

Net profit fell 40.4% YoY to 43.8 Cr, with diluted EPS at 4.83. For 9M FY26, revenue was 1217.9 Cr, a 1.9% YoY drop, and profit was 126 Cr, down 25.2% YoY.

Xanthine derivatives contributed almost half of Q3 revenue, with international sales comprising 53% of 9M geographical sales.

The company is expanding Xanthine derivative capacity to 9,000 MTPA and developing the new Atali greenfield site (400 Cr investment) for CDMO/CMO and intermediates.

The Xanthine expansion is on track for mechanical completion by March '26. However, Atali's Phase 1 is currently facing operational challenges, expected to be resolved by Q4 FY26. An additional 49 Cr of CDMO goods were in transit, impacting Q3 revenue.

Management projects 30-40% CDMO revenue growth for FY26 and marginal EBITDA growth.

The API business continues to face margin pressure.